ArticleInternational journal of nanomedicine2026
Stimuli-Responsive Calcium Phosphate Nanoreactor for Synergistic Chemo-Photothermal-Ferroptosis Therapy of Colorectal Cancer.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer therapy encounters major obstacles, including insufficient tumor targeting, systemic toxicity, and the emergence of drug resistance, underscoring the need for advanced therapeutic modalities. This work aimed to engineer a multi-mechanism synergistic nanoplatform to surmount these limitations. Methods: A hyaluronic acid-modified calcium phosphate nanoparticle construct (CaPHDH) was developed incorporating a dual-action mechanism via calcium ion chelation and hydrophobic entrapment. Hemin was encapsulated within the calcium phosphate lattice via a green synthesis approach, followed by electrostatic loading of doxorubicin (DOX). The nanoparticles were comprehensively characterized for physicochemical properties. Antitumor efficacy was assessed in vitro in CT26 colorectal carcinoma cells and in vivo in a CT26 tumor-bearing murine model, with or without 808 nm laser irradiation. Mechanistic investigations, including ferroptosis and immune activation, were conducted. Results: The CaPHDH nanoparticles exhibited a uniform size of approximately 100 nm, excellent dispersibility, pH-triggered drug release, and high photothermal conversion efficiency. In vitro, treatment produced a markedly enhanced anti-tumor effect against CT26 cells under 808 nm laser irradiation, attributable to the synergistic actions of chemotherapy, photothermal therapy, and ferroptosis induction. In vivo, CaPHDH achieved effective tumor-specific accumulation and, upon laser irradiation, yielded superior tumor growth inhibition relative to monotherapies. In addition, CaPHDH treatment significantly promotes the polarization of tumor-associated macrophages (TAMs) toward the M1 phenotype, thereby reshaping the tumor immune microenvironment. Comprehensive biosafety assessments indicated no significant systemic toxicity, organ damage, or abnormal alterations in standard blood biochemical parameters. Conclusion: This study successfully developed a biosafety-optimized nanodelivery platform, CaPHDH, which integrates chemotherapy, photothermal therapy, and ferrocide induction. This platform enables highly effective synergistic treatment in a mouse rectal cancer model, offering new insights into combination therapy strategies for tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.